Characterization of AAV vectors: A review of analytical techniques and critical quality attributes July 03， 2026 The 2024 Molecular Therapy: Methods & Clinical Development by
In vivo generation of CAR T cells: biology, delivery platforms, clinical promise, and translational challenges June 26， 2026 The 2026 Blood Immunology & Cellular Therapy
Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging June 18， 2026 The 2019 JCI Insight by Mazur, C., et al., researches Brain pharmacology
Systemic delivery of AAV5, AAV8, and AAV9 packaging a C5-12-microdystrophin-FLAG expression cassette in non-human primates June 12， 2026 The 2025 Mol Ther Methods Clin Dev
Controlled linking of AAV capsids enables coordinated multi-vector deliver June 05， 2026 The 2026 Engineering, Medicine by Kim, Y., et al., et al. researches Controlled
Improved targeted delivery of antisense oligonucleotide with an antibody mask May 29， 2026 The 2025 Nucleic Acids Research by Hsia, H.E., et al. researches Improved
A framework for individualized splice-switching oligonucleotide therapy May 22，2026 The 2023 Nature by Kim, J., et al. researches A framework for individualized splice-switching oligonucleotide therapy.
PRESENTING CLINICAL TRIAL DATA ON NEXT-GENERATION AAV VECTOR FOR SPINAL MUSCULAR ATROPHY AT ASGCT 2026 May 20，2026 Development of the next generation of AAV vector
Safety and Efficacy of cceAAV-aflibercept-Fc-YTE (F-CRG-B191): A Gene Therapy for Neovascular Age-Related Macular Degeneration May 15， 2026 The 2026 Invest Ophthalmol Vis Sci by Shi,